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Available online 7 June 2016AbstractThe interaction between ephrin ligands (efn) and their receptors (Eph) is capable of inducing forward signaling, from ligand to receptor, as
well as reverse signaling, from receptor to ligand. The ephrins are widely expressed in many tissues, where they mediate cell migration and
adherence, properties that make the efn-Eph signaling critically important in establishing and maintaining tissue boundaries. The efn-Eph system
has also received considerable attention in skeletal tissues, as ligand and receptor combinations are predicted to mediate interactions between the
different types of cells that regulate bone development and homeostasis. This review summarizes our current understanding of efn-Eph signaling
with a particular focus on the expression and functions of ephrins and their receptors in bone.
© 2016 The Korean Society of Osteoporosis. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Ephrin ligands (also known as efn) are a family of proteins
that serve as the ligands of ephrin receptors (Eph), which
represent the largest known subfamily of receptor tyrosine
kinases (RTKs). Both efn ligands and Eph receptors are
membrane bound proteins that exert many important functions
in a variety of tissues during development and adulthood. In
bone, a number of efn ligands and Eph receptors are known to
be expressed in many cell types and have been shown to play
important roles in communication between osteoblasts and
osteoclasts that regulate their differentiation [reviewed in
Ref. [1]]. In addition to propagating Eph receptor mediated
forward signaling, one unique property of the efn ligands is
that they all have the capacity to initiate a “reverse” signal that* Corresponding author. Musculoskeletal Disease Center, Research Service
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).is distinct from the “forward” signal associated with activation
of their corresponding receptors. Efn-Eph signaling is also
known to interact with other growth factor signaling pathways
that have been implicated in skeletal development [2e4] and
maintenance [5,6]. In this review, we will focus on expression
patterns of efn ligands and Eph receptors in bone and their
mechanism of action in regulating skeletal development and
homeostasis.2. Ephrin ligand and receptor families
The efn ligands are comprised of two subfamilies, the GPI-
anchored efnA family and the transmembrane efnB family.
Eph receptors (EphA and EphB) belong to the RTK superfamily.
In general, efnA ligands bind toEphA receptorswhile,with a few
exceptions such as EphA4 and A5, efnB ligands bind to EphB
receptors. However, the affinities between ligand and receptor
pairs can vary depending on the ligand or receptor (Table 1).
Interaction of the efnA ligand with its receptor displays a “lock-
and-key” binding, while efnB ligand binding proceeds through
conformational changes that result in an “induced fit” with its
receptors [7]. The promiscuity of binding suggests that there islsevier B.V. This is an open access article under the CC BY-NC-ND license
Table 1
Mammalian ephrin ligand-receptor binding specificity.
Ligand efnA efnB
A1 A2 A3 A4 A5 A6 B1 B2 B3
Receptor EphA1 þþ        
A2 þþ þ þþþ B B B   
A3 þ þþþ þþ þþ þþþ B þ þ B
A4 þþþ þþ þþ B þþþ B  þþ B
A5 þþ þþ þþ B þþþ B   
A6 B B B B B B   
A7 þþ þþþ þþ B B B   
A8 B þþ þþ B þþþ B B B B
A10 ND ND ND ND ND ND ND ND ND
EphB1 þþ  þþ þþ  ND þþ þþ B
B2      ND þþþ þþþ B
B3 ND  ND ND ND ND þþþ þþþ þþ
B4 ND  ND ND ND ND þ þþþ B
B6 ND ND ND ND ND ND B B B
Binding affinities determined by ligand-receptor binding assays [reviewed in 72].
þ: low, Dissociation Constant (Kd) greater than 10 nM.
þþ: medium, Kd 1 nMe10 nM.
þþþ: high, Kd less than 1 nM.
: no binding detected.
B: ligand-receptor binding observed, but no data on binding affinity [19,72].
ND: no data on binding [72].
EphA9 and EphB5 are avian. EphA10 is not yet characterized for ligand binding.
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the ephrin family. The complexity of signaling is also dependent
on ligand and receptor expression in cis versus trans signaling,
which can involve clustering of ligands and receptors into higher
order structures within and between cells to further modulate
signaling [8,9]. Interactions with other intracellular signaling
pathways also occur. Signaling is terminated through the
cleaving of the extracellular ligand-receptor domains or the
endocytosis of the complex [reviewed in Ref. [10]]. Efn-Eph
signaling is therefore complex and exerts multitude functions
beyond simple expression and binding of cognate ligands and
receptors.
The interaction of ephrin ligands and receptors can activate
a bidirectional signal in which receptor (forward) or ligand
(reverse) signaling activate downstream signaling cascades to
produce various outcomes [reviewed in Refs. [11,12]]. For-
ward signaling is generally mediated through phosphorylation
and activation of the receptor protein-tyrosine kinase activity.
While reverse signaling is known to be mediated through the
PDZ (postsynaptic density 95/discs-large/zona occludens-1)
binding domain in efnB ligands, it is not well characterized
in the efnA ligands, which lack an intracellular domain. EfnA
ligand reverse signaling is therefore thought to proceed
through associations with non-ephrin intracellular partners.
These efn-Eph bidirectional signaling mechanisms can
mediate complex functions within and between tissues, and
are therefore of great interest in tissue development and repair.
3. Role of efn-Eph signaling in tissue development
Efn-Eph signaling is predicted to be an important mediator
of tissue development and patterning, where efn-Ephinteractions define the spatial boundaries between tissues and
maintain segment boundaries. The efn-Eph system have been
established to regulate both cell adherence and cell migration
during development, and can act as attractants and repellants
between cells within and between tissues, but these functions
can depend on the cell context in which they are expressed
[reviewed in Ref. [10]].
During embryonic development, efnB2 patterns the somites
and regulates neural crest cell migration [13,14]; these struc-
tures contribute to the formation of a diverse set of tissues,
including skeletal tissues. Efn-Eph regulation of neurogenesis
has been one of the better studied areas of tissue development
[reviewed in Ref. [15]], and several ephrin ligands and re-
ceptors expressed in neural tissues have been identified in
bone. Studies in knockout mice identified efnB-EphB forward
[16] and reverse [17] signaling as key in regulating axon
fasciculation and guidance, respectively. The efnA family also
regulates axon guidance in chick embryos. In this case the
relative cell surface levels of efnA ligand and EphA receptor
expression determine the migration of axon growth cones,
with forward signaling generally inhibiting and reverse
signaling generally promoting the growth cone survival [8]. It
is probable that the efn-Eph regulation of neural tissue
development might also be important for bone development,
as the periosteum, which mediates bone growth and repair, is a
highly innervated tissue.
Ephrin regulation of the vasculature has also received
considerable attention, and is especially important in bone, a
normally highly vascular tissue that must establish the blood
supply during development and re-establish it under the hyp-
oxic conditions that result from tissue injury. The ossification
process itself requires the entry of osteogenic cells to the
67C.H. Rundle et al. / Osteoporosis and Sarcopenia 2 (2016) 65e76nascent bone through the vasculature. Ephrins regulate the
formation of networks of embryonic blood vessels through
reciprocal repulsive cellecell signaling [18,19]. As in neural
tissues, several members of the efn A and B families of ligands
and receptors expressed in bone are also expressed in endo-
thelial cells, suggesting that they regulate communication
between bone cells and endothelial cells in the developing
skeleton. For example, EfnB1 and EphB2 participate in
sprouting and epithelialemesenchymal interactions [18], and
efnB2 [20] and EphB4 expression marks the boundaries of the
arterial and venous endothelium, respectively [reviewed in
Ref. [21]]. Global knockout mice lacking EphB2 exhibit se-
vere defects in angiogenesis of both arteries and veins and do
not survive, implicating this ligand in the endothelial and
mural cell motility and adhesion in the cardiovascular system
[22]. In vitro, efnB1 expression is induced in response to
stimulation by vascular endothelial growth factor (VEGF) in
mesenchymal stem cells [23], suggesting that cells with
osteogenic potential can mediate angiogenesis. EphB1
signaling to efnB1 promotes integrin-mediated cell motilityTable 2
Efn ligand and Eph receptor expression in skeletal tissues.
Ephrin Skeleta
efn (ligand) Cell/Tissue type Approa
efnA1 Osteoblast precursors/osteoclast precursors RT-PC
efnA2 Osteoblast precursors RT-PC
efnA4 Osteoblast precursors RT-PC
efnA5 Osteoblast precursors RT-PC
efnB1 Osteoblast precursors/osteoclast precursors RT-PC
Limb prechondrogenic condensations IHH
efnB2 Osteoblast precursors/osteoclast precursors RT-PC
Embryonic calvarial sutures lacZ ex
Osteoblasts/osteocytes/osteoclasts Microa
Osteoblasts/osteocytes/osteoclasts IHH, I
OA gene expression In vitro
Eph (receptor) Cell/Tissue type Approa
EphA1 Osteoblast/osteoclast precursors RT-PC
EphA2 Osteoblast/osteoclast precursors RT-PC
EphA3 Osteoblast precursors RT-PC
Bone marrow MSC Microa
EphA4 Osteoblast/osteoclast precursors/osteoclasts RT-PC
Chicken limb bud IHH
EphA7 Osteoblast precursors RT-PC
HoxA13 KO limb mesenchyme IHH, I
EphB1 Calvarial osteoblasts RT-PC
Embryonic calvarial sutures lacZ-kn
EphB2 Osteoblast precursors RT-PC
Embryonic rib perichondrium, calvarial sutures lacZ-kn
Limb mesenchyme IHH
EphB3 Osteoblast precursors RT-PC
efnB1 mutant palate IHH
Limb mesenchyme IHH
EphB4 EphB4 transgenic osteoblast precursors RT-PC
Fracture hypertrophic chondrocytes, osteoblasts Col-I t
OA subchondral bone IHH, R
EphB6 Osteoblast precursors RT-PC
IHH, immunohistochemistry; ISH, in situ hybridization; KO, knockout; MSC,
polymerase chain reaction.and attachment in Chinese Hamster Ovary (endothelial) cells
[24]. The number of ephrin ligands and receptors expressed in
bone and in the developing vasculature and the importance of
angiogenesis in bone development and repair suggest that the
efn-Eph signaling is critical in establishing and maintaining
vascularity in bone.
4. Role of efn-Eph signaling in tissue repair and pathology
Ephrin ligands and receptors are expressed during tissue
repair, with expression best characterized in ischemia and
optic nerve spinal cord injuries. Ephrin ligands and receptors
also function in inflammatory conditions [reviewed in
Ref. [25]]. EfnB1 and EphB1 enhance lymphocyte migration
in rheumatoid arthritis [26], which could contribute to the
inflammatory reaction in this pathologic condition, suggesting
that they can also mediate a normal tissue post-injury in-
flammatory response. EfnB1 and efnB2 mediate PECAM-1
functions in endothelial cells, destabilizing endothelial cell
junctions and promoting the motility of monocytes expressingl tissue expression Reference
ch Effect
R Enhanced osteoclastogenesis [35]
R Increased EphA2 osteoclastogenesis [35]
R [35]
R [35]
R [5]
[2]
R, Western Blot [5]
pression [73]
rray/RT-PCR/IHH Response to PTH, PTHrP [38]
GF-1R KO [39]
activation [49]
ch Effect
R [35]
R, Western Blot Reduced efnA2 osteoblastogenesis [35]
R [35]
rray/RT-PCR Response to hypoxia [74]
R [5,35]
[34]
R [35]
SH [33]
R [5]
ockin [73]
R [5]
ockin [73]
[2]
R [5]
[41]
[2]
R [5]
ransgenic Increased fracture callus bone [48]
T-PCR [49]
R [5]
mesenchymal stem cells; OA, osteoarthritis; RT-PCR, reverse transcription-
Table 3
Models of skeletal efn ligand and Eph receptor function.
Ephrin Model Biological effects Reference
efn (ligand)
efnA1 Global KO Vertebrae number, vertebrae transformation, kinked tail vertebrae [75]
efnA2 In vitro Increased osteoclastogensis, decreased osteoblastogenesis [35]
efnA4 Mutant Cranial development [76]
efnB1 Mutant Craniofacial development [41]
PGK KO Perinatal lethal, rib, sternum, carpal patterning [2]
Global KO Perinatal lethal, polydactyly [3]
Neural crest cell KO Craniofacial development [3]
PDZ mutant Craniofacial development [3]
OB KO Calvarial development, decreased bone size, mineralization [36]
Myeloid KO Increase OC differentiation, resorption [37]
In vitro Osteoblasts in response to alendronate [55]
In vitro Human MSC chondrogenic/osteogenic differentiation (with efnB2) [40]
Col-I transgenic Bone formation response [43]
efnB2 OB KO Decreased osteoblast differentiation, increased apoptosis [53]
OC KO Decreased osteoclast differentiation [5]
In vitro Human MSC osteogenic differentiation [40]
In vitro activation OA gene expression [50]
Eph (receptor)
EphA1 Global KO Kinked tail vertebrae [77]
EphA2 In vitro Osteoclast/osteoblast precursors [35]
Global KO Kinked tail vertebrae [78]
EphA4 In vitro Osteoclast/osteoblast precursors [35]
In vitro Reduced osteoclast activity [47]
Global KO Craniosynostosis [44]
EphB1 Global KO Reduced calvarial bone [73]
In vitro Osteoblasts in response to alendronate [55]
EphB2/EphB3 PGK KO/truncation Cleft palate [42]
EphB3 In vitro Osteoblasts in response to alendronate [55]
EphB4 In vitro Growth plate prehypertrophic chond, OB, OC differentiation [39]
Col-I transgenic Promotes fracture callus endochondral ossification, inhibits remodeling [48]
IHH, RT-PCR In vitro efnB2 activation of OA subchondral bone [50]
Chond, chondrocyte; IHH, immunohistochemistry; KO, knockout; MSC, mesenchymal stromal cell; PDZ, postsynaptic density 95/discs-large/zona occludens-1
domain; OA, osteoarthritis; OB, osteoblast; OC, osteoclast; PGK, phosphoglycerate kinase; RT-PCR, reverse transcription-polymerase chain reaction.
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normal component of the inflammation that occurs in post-
injury tissues.
Importantly, the involvement of efn-Eph signaling in cell
motility and adhesion also implicates dysregulation of efn-Eph
signaling in cancer progression and tumor growth [reviewed
by Refs. [28,29]], including bone-related cancers such as
multiple myeloma and osteosarcoma [reviewed in Ref. [30]].
EphB2 can mediate cell migration or adenoma cell prolifera-
tion to carcinoma, depending on whether the intracellular
signaling is phosphatidylinositol 3-kinase (PI3-K)-mediated or
cyclin D1-mediated, respectively [31]. The recently described
EphA10, although also expressed in several normal tissues, is
expressed in triple negative breast cancers [32]. These obser-
vations establish the efn ligands and their receptors as critical
mediators of cell motility in pathologic conditions, including
those of skeletal tissues.
5. Efn-Eph expression in bone
While the expression of efn ligands and their receptors have
been more extensively studied in the context of nervoussystem development, efn-Eph expression in bone development
remains only partially characterized. Ephrin ligands and their
receptors are expressed in embryonic tissues that form the
skeleton (Table 2). Specifically, efnB1 is expressed in the
prechondrogenic mesenchymal condensations and efnB2 is
expressed in the embryonic calvarial sutures. EfnB1, EphB2
and EphB3 are expressed at the tips of the ribs where they
would be expected to regulate rib development. With respect
to Eph receptors, EphB1 and EphB2 are also expressed in the
embryonic calvarial sutures, and EphA3 and EphA7 are
expressed in the limb mesenchyme [33]. EphB4 is expressed
in the chondrocytes, osteoblasts and osteoclasts of the growth
plate. EphA4 is expressed in the prechondrogenic limb
mesenchyme of the chicken [34]. These associations suggest
that these ligands and receptors might be binding partners that
regulate the development and homeostasis of both intra-
membranous and endochondral bone.
Studies at the cellular level have identified multiple efn
ligands and Eph receptors expressed by cells of osteoblast and
osteoclast lineage, as well as their precursors [5,35]. EfnB1,
efnB2 and EphB receptors are expressed throughout osteoblast
development, but more restricted in osteoclast precursors.
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blasts [36] and osteoclasts [37] have revealed that efnB1
expressed in both osteoblasts and osteoclasts regulates skeletal
development by influencing bone formation and bone resorp-
tion processes, respectively.
The expression of both ligands and receptors is predicted to be
under the control of osteoregulatory agents; for example, para-
thyroid hormone (PTH) and parathyroid hormone related protein
(PTHrP) are known to regulate efnB2 expression in osteoblasts.
The treatment of mice with PTH and PTHrP, both established
enhancers of bone formation, resulted in an increase in efnB2
gene expression inmouse bonemarrow stromal cells, suggesting
that this ligand promotes PTH-mediated bone formation [38].
Other osteogenic growth factors have been associated with
ephrin regulation. Studies of bone cells isolated from osteocalcin
cre-driven (i.e., osteoblast-specific) insulin-like growth factor
(IGF)-I receptor (IGF-1R) knockout mice demonstrated that
inhibition of efnB2 and EphB4 communication impairs IGF-I-
mediated differentiation of osteoblasts and osteoclasts in co-
cultures. Col-II cre-driven (i.e., chondrocyte-specific) IGF-IR
knockout mice exhibited a decreased expression of efnB2 and
EphB4 in vivo. Inhibition efnB2-EphB4 signaling in a chon-
drocyte cell line in vitro performed in these studies identified a
reduced expression of collagen markers of chondrocyte differ-
entiation. Taken together, these results indicate that EphB4 and
efnB2 expression in growth plate chondrocytes, and EphB4 and
efnB2 expression in growth plate osteoblasts and osteoclasts,
respectively, promote bone cell development and endochondral
bone growth [39].
6. Role of ephrins in skeletal development
Identification of the molecular pathways that regulate bone
formation is important to understand bone regeneration and to
develop therapeutic applications for bone injuries and dis-
eases. Recent studies that target disruption of efnB ligands and
their receptor genes to skeletal tissues in vivo, together with
in vitro studies, now demonstrate a significant role for the efn
ligands and their receptors in bone development (Table 3). For
example, efnB1 and efnB2 interactions with the EphB re-
ceptors mediate the diverse processes of marrow-derived
mesenchymal stromal cell attachment and spreading, and
chondrogenic and osteogenic differentiation, respectively [40].
The initial demonstration of efnB1 effects on bone forma-
tion was derived from a mutant efnB1 mouse, which displayed
craniofacial deformities in skeletal patterning. Mice with a
disruption of efnB1 expression exhibited similar characteristics
to cleft palate seen in patients with efnB1 mutations [2,3],
where efnB1 specifies the position of the frontal coronal suture.
The efnB1 knockout models have also identified ligand func-
tions in the regulation of limb development, with efnB1 dys-
regulation producing polydactyly in a knockout mouse strain
[2,3]. These studies established that efnB1 regulates skeletal
patterning by defining tissue boundaries, particularly those of
the mesenchymal-perichondral tissues during the development
of the digits and the ribs, where it mediates the splitting of
mesenchymal condensations to individual ribs or digits [3].Changes in EphB3 expression in this efnB1 mutant iden-
tified EphB3 as a possible binding partner for efnB1 regulation
of craniofacial development [41]. However, the single
disruption of EphB1, B2, B3 or A4 receptors, the major re-
ceptors of efnB1 signaling, did not produce calvarial or other
skeletal defects, although the combined deficiency of both
EphB2 and EphB3 in a knockout/mutant mouse line resulted
in a cleft palate [42] similar to the skeletal patterning defect
observed in the efnB1 knockout [2]. These results suggest a
degree of functional redundancy among Eph receptors in this
tissue.
Although presenting a dramatic phenotype for the study of
bone development, the global efnB1 knockout was also
embryonic lethal. With respect to conditional knockouts,
Wnt-cre-driven deletion of efnB1 in neural crest cells
also produced the craniofacial phenotype. Additionally,
the palatal defect was observed in an embryonic PDZ
signaling mutant, establishing efnB1 reverse signaling func-
tions for this phenotype [3]. Because efnB1 mediates several
aspects of skeletal development, viable conditional knock-
outs with efnB1 deficiency in a specific skeletal tissue
present better models for bone metabolism studies in adult
subjects.
Recent findings in conditional knockout mouse models
have further demonstrated an important role for ephrins in
bone metabolism. The osteoblast-specific knockout of efnB1
in mice resulted in a reduced body length, smaller bone size,
and reduced bone formation at three weeks of age [2]. A
comparison of the bones in osteoblast-specific efnB1 knockout
mice and wild-type mice by dynamic histomorphometry
established that efnB1 expression promoted bone growth at the
periosteum [36]. Conversely, transgenic mice that overexpress
efnB1 in osteoblasts under the control of the Col-I promoter
displayed an enhanced periosteal bone formation in response
to mechanical loading [43]. These data indicate that efnB1
functions regulate bone formation at the periosteum during
skeletal development and in response to bone injury, and that
manipulating efnB1 expression to promote bone formation
similar to that observed in development might indeed be
applicable for fracture therapy.
In addition to the different RTK pathways associated with
forward efnA and B ligand signaling to EphA and B receptors,
different cell surface and growth factor family and signaling
molecule proteins have been demonstrated to interact with
EphA and EphB receptors. These cell surface interactions
provide additional complexity to EphA and EphB receptor
signaling pathways. Proteins interacting in cis with Eph re-
ceptors include claudin-4 with EphA2, “a disintegrin and
metalloproteinase domain-containing protein” (ADAM)10
with EphA3, the fibroblast growth factor receptor (FGFR)
family with EphA4 and E-cadherin with EphB3. Protein in-
teractions in cis have been experimentally demonstrated for
connexin43 and g-secretase with efnB1 and B2, metal-
loproteinase with efnB2 and the N-methyl-D-aspartate receptor
(NMDAR) with efnB2 and B3. Cell surface protein in-
teractions in trans have also been demonstrated between
efnB1 and claudins 1 and 4 [reviewed in Ref. [12]].
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Ephrin signaling promotes bone and cartilage formation,
and regulates bone formation and bone remodeling to maintain
skeletal homeostasis. Because bone cells express ligands and
receptors of the efnA and B families (Table 2), the activation
of forward and/or reverse signaling and subsequent regulation
of cell function is probably frequent, given the cell-to-cell
contact between bone cells. Bidirectional ephrin signaling
between osteoblasts and osteoclasts that coordinates their
development has been referred to as “coupling”, although a
conclusion of activation or differentiation as a direct result of
forward and reverse signaling between an interacting efn-Eph
pair must also consider the possibility that the cellular
response does not utilize this efn-Eph pair.7.1. EfnA-EphA forward signalingIn addition to intracellular interactions signaling through
the tyrosine kinase domain, forward signaling to EphA re-
ceptors can involve a variety of interactions with ephrin and
non-ephrin proteins that introduce additional layers of
complexity to ephrin signaling [1].
Knockout mouse studies have demonstrated that EphA re-
ceptor signaling regulates bone formation. The inhibition of
EphA4 signaling in EphA4 knockout mice demonstrates that
EphA4 results in craniosynostosis. Forward signaling through
EphA4 normally excludes osteogenic precursor cell migration
to the coronal suture of the calvaria. The failure to limit this
migration in the EphA4 knockout mouse, as well as the
disruption of EphA4 mediation of Twist1 functions, produces
the calvarial suture fusion in this condition [44].
EfnA-EphA signaling regulates angiogenesis, an important
aspect of bone formation and repair. In vitro inhibition of EphA2
expression and functions promote endothelial cell migration and
angiogenesis in response to VEGF but not fibroblast growth
factor (FGF)2, growth factors both expressed in bone, suggesting
potential modulation of angiogenesis by ephrin and other growth
factor families in the bone vasculature [45].
EphA receptor signaling has been associated with several
different malignancies [reviewed in Ref. [28]], including the
metastasis of prostate cancer to bone, although this dysregulation
is not well studied. Studies also indicate that EphA2 forward and
reverse signaling functions can even display ligand-independent
functions in mediating opposite directions of the epithelial
mesenchymal transition (EMT), with ligand-independent
signaling promoting the mesenchymaleepithelial transition
(MET) and ligand-independent signaling promoting EMT
[reviewed in Ref. [46]]. Although EphA2 is expressed during
bone cell differentiation, ligand-independent EphA receptor
signaling has not been characterized in bone. Forward signaling
in the ephrinA family is discussed in other reviews [1,46].7.2. EphA-efnA reverse signalingEfnA ligands and EphA receptors also mediate communi-
cation between osteoblasts and osteoclasts in bone celldevelopment through forward and reverse signaling. In vitro
studies have demonstrated that efnA2 expression was induced
by NF-kB in osteoclasts, consistent with RANK regulation of
osteoclast development, and was c-Fos dependent, indicating
that efnA2 promoted the development of osteoclast precursors.
Because EphA2 expression also suppressed osteoblast differ-
entiation in co-culture with osteoclasts, efnA2-EphA2
signaling between osteoclasts and osteoblasts, respectively,
would be expected to promote osteoclast differentiation and
enhance bone remodeling over bone formation prior to efnB-
EphB regulation of this circuit [35]. In vivo, the deletion of
EphA4 in osteoclasts promoted osteoclast activity and bone
remodeling, reduced cortical and trabecular bone volume and
mineralization, thus establishing its importance as a negative
regulator of osteoclast activity [47]. Mechanistically, EphA-
efnA reverse signaling is not well characterized, but EphA4
might act by sequestering the efnA2 ligand to modulate its
signaling in osteoclast development [35]. Alternatively,
because EphA4 is one of the EphA receptors that can bind
efnB ligands, its binding could mediate reverse signaling
through efnB1 or efnB2 in pre-osteoblasts, osteoblasts and
osteoclasts, much as EphB receptors mediate reverse signaling
through efnB ligands (Table 1).7.3. EfnB-EphB forward signalingAs with the EphA receptors, forward signaling to EphB
receptors can also involve a variety of intracellular interactions
that mediate the interactions of ephrin and non-ephrin proteins
and introduce additional layers of complexity to ephrin
signaling [1].
EfnB1 and EphB receptors are expressed in bone and the
vasculature (Table 2), and might regulate bone and vascular
cell communication. EfnB1, efnB3 and EphB2, EphB3 and
EphB4 regulate the formation of the vasculature. EfnB2 per-
icyte/vascular smooth muscle cell knockout mice exhibit
defective vessel development due to defective cell motility,
migration and cell matrix adhesion [22]. Along with EphB4
expression in venous cells, efnB2 defines the arterial and
venous boundaries of the developing vasculature [18e20].
Because the vasculature is critical to developmental ossifica-
tion and reestablishing the blood supply is so important for
bone repair, further investigation is needed to establish ephrin
communication between the bone and vasculature.
With respect to bone repair, Col-I (osteoblast)-specific
overexpression of EphB4 in mice increases fracture callus
bone formation and inhibits remodeling, although this regu-
lation has not been fully characterized [48]. Forward signaling
through the EphB receptors has also been associated with
pathologic skeletal conditions. EphB4 expression was
increased in osteoarthritis (OA) chondrocytes but reduced in
response to efnB2 treatment [49]. Further studies demon-
strated that the in vitro application of efnB2 to osteoarthritic
(OA) chondrocytes [50] and resorption-promoting sub-
chondral bone osteoblasts inhibited the expression of the in-
flammatory genes interleukin (IL)-1b and IL-6, as well as the
matrix degrading matrix metalloproteinase (mmp) genes
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therapeutic approach for alleviating cartilage degradative
enzyme functions in OA that regulates the expression of these
two ephrins in OA chondrocytes, and in what the authors refer
to as “proresorption” osteoblasts, might indeed be utilized to
inhibit abnormal resorption in OA [50].7.4. EphB-efnB reverse signalingReverse signaling through efnB1 was demonstrated to be
important in bone development in an efnB1 signaling-deficient
mutant. The global efnB1 knockout mouse exhibited a wide
range of skeletal phenotypes attributed to impaired forward
signaling, but a mutation that deleted the efnB1 PDZ domain
produced a mouse with defective neural crest cell migration,
an effect attributed to reverse signaling through efnB1 [3]; this
approach resolved efnB1-mediated forward and reverse
signaling in skeletal development. Several EphB receptor
candidates are expressed in osteoblast development that could
mediate reverse signaling through efnB1. Other studies
established that reverse signaling through EphB2 and medi-
ated by PI3-kinase was enhanced in TGFb3-dependent palate
fusion in the chicken [51], demonstrating skeletal defects
similar to the reverse signaling functions of efnB1 deficiency.
In agreement with these conclusions, the application of EphB2
increased Osterix expression and bone formation marker
expression in an osteoblast-specific efnB1 knockout mouse
[36].
EfnB2 signaling also regulates cartilage remodeling. In
cartilage, efnB2 forward and reverse signaling might proceed
through the sequestration of efnB2 expression in chon-
drocytes, regulating the expression of the cartilage remodeling
enzyme “a disintegrin and metalloproteinase domain-
containing protein with thrombospondin motifs” (ADAMTS)
4 in Osterix-expressing hypertrophic chondrocytes [52]. This
study postulates that the efnB2-dependent production of
cartilage degrading enzymes such as ADAMTS4 that are
required for osteoblast and osteoclast attachment to the carti-
lage is impaired, which inhibits remodeling during endo-
chondral bone formation.
Studies indicate that the differential expression of efn li-
gands and Eph receptors and forward and reverse signaling
between osteoblasts and osteoclasts might coordinate bone
formation and bone resorption. EfnB2-EphB4 signaling be-
tween osteoclasts and osteoblasts has been postulated to co-
ordinate osteoclast-mediated resorption with osteoblast-
mediated bone formation in vitro, as well as in vivo in
knockout and transgenic mouse models. Transgenic over-
expression of EphB4 in osteoblasts resulted in increased bone
formation, thus suggesting a role for forward signaling in bone
formation, while osteoclast lineage deletion of efnB2
increased bone resorption, suggesting that efnB2 reverse
signaling suppresses osteoclast formation, possibly by inhib-
iting RANKL expression [5]. When efnB2 deletion from os-
teoblasts was driven by Osterix-cre expression, osteoblast
differentiation and bone formation were impaired and there
was an increase in expression of the markers of apoptosis,indicating that efnB2 signaling mediated osteoblast survival
[53]. Further evidence in support of this regulation was ob-
tained in studies where the inhibition of EphB4 communica-
tion with efnB2 in osteoblasts impaired the anabolic effect of
PTH on bone formation, restricting both osteoblast develop-
ment and the support of osteoclastogenesis [54]. These ob-
servations also make efn-Eph signaling an obvious candidate
for the development of therapeutic approaches in challenging
situations such as osteoporosis, where bone formation and
resorption are unbalanced. They also imply that impaired bone
healing might benefit from efn/Eph-related therapy to promote
bone formation.
Interestingly, in vivo treatment of mice with alendronate
enhanced efnB1 expression in pre-osteoclasts, and enhanced
EphB1 and EphB3 expression in osteoblasts co-cultured with
osteoclasts from these mice. The inhibition of osteoblast
development marker expression in vivo suggested that the
effect was produced by forward signaling between the efnB1
ligand on osteoclasts, and that the EphB receptors on osteo-
blasts reduced osteoblast function to balance it with reduced
osteoclast function [55]. EfnB1 was also demonstrated to
reduce osteoclast functions in response to reverse signaling
from EphB2 treatment in vitro, as it has in response to deletion
in a myeloid-specific efnB1 knockout mouse in vivo [37].
Ephrin signaling can mediate other regulatory pathways that
regulate bone homeostasis. For example, mechanical loading
increases the periosteal bone formation in efnB1 transgenic
mice, and increases EphB2 expression in bone [43]. The
increased EphB2 expression in a mechanically loaded bone
promoted Osterix expression through reverse signaling to
efnB1 and further stimulated bone formation, implying that
bidirectional signaling through EphB2 and efnB1 regulated this
effect, and that EphB2-activated efnB1 reverse signaling might
coordinate periosteal osteoblast proliferation and angiogenesis
for bone homeostasis. EfnB2-EphB2 reverse signaling regu-
lates the inflammatory differentiation of endothelial cells [27],
suggesting that reverse signaling might mediate normal post-
injury and pathological inflammation in bone.
8. Ephrin signaling in the stem cell niche
EphB2-efnB1 and EphB4-efnB2 signaling regulates
communication between mesenchymal stromal cells (MSC)
and hematopoietic cells. The inhibition of reverse signaling
from EphB2 to efnB1 or efnB2 forward signaling to EphB4 in
MSC inhibited T cell activation [56]. Other studies that
examined stromal support of the hematopoietic niche
demonstrated that stromal cells from Col-I-cre EphB4 trans-
genic mice supported hematopoietic growth factor production
and bone marrow reconstitution [57]. These results support a
role for ephrin signaling from bone cells in maintaining the
hematopoietic stem cell niche of the bone marrow.
9. Efn-Eph intracellular signaling
Cell adherence, shape and motility depend on the intra-
cellular signaling mechanisms activated by EphA and B
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reverse signaling. The EphA and B receptors signal through
the Rho and Ras GTPases that mediate actin dynamics
[reviewed in Ref. [1]]. EphA-activated Rho GTPases mediate
cell shape and movement though specific adapter proteins,
while EphB-activated GTPases use a different set of adapter
proteins to mediate actin filament elongation. Eph receptors
also regulate the MAP kinase pathway through Ras GTPases.
This pathway regulates transcription, proliferation and
migration, as well as adhesion; its regulation by EphA and B
receptors is generally negative. EphA receptors also regulate
the Jak/Stat pathway, and EphB receptors regulate PI3-K-
mediated proliferation.
The highly conserved cytoplasmic tail of the efnB ligands
contains several tyrosine residues that can be phosphorylated
when the extracellular domain of an efnB ligand interacts with
an EphB receptor. However, this signaling pathway is subject
to several types of modulation. Intracellular reverse signaling
pathways of efnA ligands are glycosylphosphatidylinositol
(GPI)-linked and are less well characterized. Accurate regu-
lation of ephrin signaling and the cross-talk between the
ephrin and growth factor intracellular signaling pathways that
mediate cell proliferation, migration and invasion is critical in
maintaining tissue homeostasis and avoiding the development
of cancer [29].
Ephrin signaling regulates various aspects of bone ho-
meostasis. Retroviral augmentation of EphA2-efnA2 reverse
signaling in vitro increased NFATc1 and c-Fos transcription,
suggesting that this signaling circuit promoted the differenti-
ation of osteoclasts [35]. EphA2 forward signaling was pro-
posed to inhibit osteoblast differentiation by reducing Osterix
and Runx2 activity [35]. In combination with this EphA2 in-
hibition of osteoblast development, these studies suggest that
efnA2-EphA2 signaling initiated a bone remodeling phase.
The authors of this study propose that an EphA2-mediated
increase in intracellular RhoA signaling might inhibit osteo-
blast differentiation. EfnB2-EphB4 forward signaling pro-
motes osteoblast differentiation via a reduction in RhoA
signaling that is thought to modify cell division, as well as the
cytoskeletal properties and motility of osteoblasts [58]. Thus,
both ephrinA and B family signaling is implicated in the
regulation of osteoblast development.
Intracellular signaling by which ephrins regulate osteoclast
development and activity also utilizes non-ephrin molecular
pathways. In the RAW264.7 pre-osteoclast cell line, Dishev-
elled2 (Dvl2) co-precipitation with efnB2 was increased by
RANKL treatment and reduced by EphB4 treatment, indicating
that Dvl2 could be a downstream effector of reverse signaling
that associates with efnB2 and mediates cell migration [59]. It
has been also recently shown that EphA4 regulates osteoclast
activity by modulating b3-integrin functions [47], presumably
by promoting attachment to the extracellular matrix. Thus, it is
likely that a multiple forward and reverse intracellular signaling
pathways are involved in mediating diverse efn-Eph effects in
different types of bone cells.
An examination of efnB1 mutations in human cranio-
frontonasal syndrome revealed that a significant proportion ofthe mutations occurred in the C-terminal 33 amino acids of the
intracellular PDZ motif [60]. A deletion of the PDZ binding
motif at the C-terminal tail abolished efnB1 binding to PDZ
proteins and impaired neural crest cell function and calvarial
formation, indicating that the PDZ signaling domain was
critical for correct bone patterning and formation [36]. With
respect to reverse signaling through efn ligands, there is
considerable flexibility for interactions with PDZ and non-
PDZ proteins [61], and the potential for the formation of
additional complex regulatory networks also exists between
their signaling pathways [62]. In addition to tyrosine phos-
phorylation, there is evidence for the phosphorylation of serine
residues of efnB1 by serine/threonine kinases to facilitate the
binding of adapter proteins. At later steps in reverse signaling,
efnB1 clusters recruit the PDZ domain-containing protein
tyrosine phosphatase PTPN13, which dephosphorylates the
efnB1 tyrosine kinase, thereby shifting signaling from
phosphotyrosine-dependent signaling pathways to PDZ
domain-dependent signaling pathways of interacting cyto-
plasmic molecules that presumably modulate efnB ligand
signaling [63]. There are over 300 interactions of these PDZ-
interacting molecules with PDZ that could regulate different
cellular processes, including the wnt receptors frizzled 1, 4 and
7, the calcium mobilizer adenine purinoreceptor 1 (P2RY1),
the cytoskeletal regulators syndecans 1, 2, 3 and 4, the tight
junction protein claudin 1, and NMDAR2A and B [64].
The C-terminus of the efnB ligand contains a conserved
binding motif (YYKV) to which PDZ-binding transcriptional
co-activating factors can bind and interact with other tran-
scription factors. One such transcriptional co-activating factor
implicated in efnB ligand reverse signaling is TAZ (tran-
scriptional co-activator with PDZ binding motif). The C-ter-
minus of TAZ bears a PDZ binding motif that localizes TAZ to
discrete nuclear foci essential for transcriptional activation, as
well as binding to the cytoplasmic tails of transmembrane
receptors and the actin cytoskeleton.
Studies on transcriptional regulatory mechanisms in bone
cells have revealed an important role for TAZ in mediating
osteogenic differentiation. For example, the increased
expression of TAZ by bone morphogenetic protein (BMP)2
stimulation is associated with an elevation in the expression of
osteocalcin, a marker of mature osteoblasts [65]. In vitro and
in vivo studies strongly suggest that TAZ functions as a
membrane/cytoskeleton-associated transcriptional regulator to
coordinate specific osteogenic and adipogenic transcription
factors and promote mesenchymal stem cell development to
bone [66]. TAZ has a highly conserved transcriptional acti-
vation WW domain that functions as a transcriptional co-
activator by binding to the PPXY motif present on a large
number of transcription factors that include Runx2, PPARg,
Smad, MEF2B, Sox9, C/EBP, Oct4 and Pax3 [reviewed in
Ref. [67]]. Observations that the Col-I (osteoblast)-specific
overexpression of TAZ enhanced bone formation in vivo
through the regulation of transcription factors suggest that
efnB ligand reverse signaling produced this effect [68]. Thus,
extracellular signals promoting bone formation are transmitted
into the nucleus through nuclear trafficking with TAZ.
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important mediators of intracellular signaling. NHERF1 con-
tains two tandem PDZ domains at the N-terminus and has
been shown to regulate trafficking and signaling of several G-
protein coupled receptors, including the PTH receptor
[reviewed in Ref. [69]]. NHERF1 is expressed in osteoblasts
and has been associated with the regulation of bone formation,
and the binding of the Na/Pi cotransporter and TAZ [70].
Targeted disruption of NHERF1 results in postnatal lethality,
often accompanied by bone fractures due to 25e30% reduc-
tion in bone mineral density [71]. NHERF1 appears to be
involved in the reverse signaling of efnB1 through the
dephosphorylation of TAZ and its relocation to the nucleus
where its osteogenic transcription factor target genes such as
Osterix are expressed [36], constituting yet another pathway of
TAZ mediation of efnB1 signaling.
10. Proposed models for the functions of ephrins in bone
Ephrin actions in bone are diverse, but require more com-
plete characterization. They are critical in determining the
skeletal pattern and in maintaining bone homeostasis. Based
upon the current literature, we propose the following model
for ephrin regulation of bone formation and resorption (Fig. 1).
In this model, different combinations of efn ligand and Eph
receptor binding partners regulate the development of osteo-
blasts, osteoclasts and chondrocytes. During the initial phases
of development in the osteogenic and chondrogenic lineages,
these interactions involve efnB1 and efnB2 binding with
EphB1/EphB2 and EphB2/EphB4, respectively. Forward and
reverse signaling involving EphB2 and EphB3 also co-
ordinates angiogenesis with bone formation, possibly through
endothelial cell expression. With respect to osteoclasts, EphA4
is inhibitory early in development, while efnA2 and EphA4Fig. 1. A model for ephrin ligand-receptor regulation of bone cell interaction in bon
growth plate development during bone growth. Interactions between osteoblasts (O
different ephrin ligand-receptor combinations, coordinating bone cell developmentcoordinate development with pre-osteoblasts. The balance
between bone formation and resorption is maintained by the
subsequent interaction of EphB4 in osteoblasts with efnB2 in
osteoclasts, which regulates osteoblast-osteoclast develop-
ment. In this way cartilage and bone formation are coordinated
with remodeling and angiogenesis.
A model of intracellular signaling pathways of efnB ligand
and EphB receptor communication that mediate bone formation
and resorption between osteoblast and osteoclast precursors is
presented in Fig. 2. Osteoblast differentiation is promoted by the
expression of osteogenic genes in response to reverse signaling
through efnB1 and forward signaling from osteoclast efnB2
through EphB4. Osteoclast differentiation is reduced by the
inhibition of osteoclast gene expression in response to reverse
signaling from osteoblast EphB4 through efnB2. The net result
of these functions in this model is bone formation.
11. Conclusions and future directions
Although it has become very clear that efn-Eph signaling
plays a key role in skeletal development and homeostasis, a
numberof key questionswith respect to the increasingly complex
ephrin regulation of bone cell communication. These questions
involve the binding preferences within and between ephrin
families of ligands and receptors, higher order clustering in-
teractions between receptors and ligands within and between
cells, the regulation of forward and reverse signaling in different
contexts, and the interactions with other ephrin and non-ephrin
extracellular and intracellular signaling pathway regulators.
Specifically:
1) Does the binding of an Eph receptor to its ligand occur by
cellecell interaction or through a cleaved receptor to the
membrane anchored ligand, or vice versa?e development and homeostasis. Several ephrin ligands and receptors mediate
B), osteoclasts (OC), endothelial cells (EC) and chondrocytes are mediated by
and activity.
Fig. 2. Intracellular EphB/efnB signaling between osteoblast and osteoclast lineage cells in bone formation. Osteoblast development is mediated by forward
signaling through EphB4 from efnB2 on osteoclasts and reverse signaling through efnB1 from EphB receptor on MSC. NERFH1 dephosphorylates TAZ for
localization to the nucleus. Osteoclast development is mediated by reverse signaling through efnB2 from EphB4 on osteoblasts. Dvl2, Dishevelled2; MSC,
mesenchymal stromal cells; NHERF, Na/H exchange regulatory factor; TAZ-P, phosphorylated TAZ.
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EphB receptor-efnB ligand interaction, or are the activa-
tion of forward or reverse signaling cell-type specific
depending on the binding partners available in a given cell
type?
3) Is reverse signaling activated via only efnB ligand inter-
action with its receptor, or does efnB ligand binding to
other proteins or activation of kinases by other growth
factors and G protein-coupled receptors activate efnB
ligand reverse signaling?
4) Does receptor-ligand interaction mainly occur via osteo-
blast-osteoblast, osteoblast-osteoclast, osteoblast-osteo-
cyte, or does it involve other cell types?
5) What are the interactions between Eph/efn signaling and
bone growth factor signaling pathways?
6) Are the Eph/efn signaling pathways involved in bone
repair similar to those of bone development and
homeostasis?
The elucidation of these functions will facilitate the opti-
mization of forward and reverse signaling strategies in the
development of therapeutic applications of the ephrins for a
wide variety of conditions in various tissues.
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